Amgen Inc. $AMGN Stake Decreased by Round Hill Asset Management

Round Hill Asset Management lessened its position in Amgen Inc. (NASDAQ:AMGN) by 2.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,323 shares of the medical research company’s stock after selling 930 shares during the quarter. Amgen accounts for 8.0% of Round Hill Asset Management’s portfolio, making the stock its 2nd largest position. Round Hill Asset Management’s holdings in Amgen were worth $11,817,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC purchased a new position in shares of Amgen during the first quarter valued at approximately $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the second quarter worth approximately $27,000. CBIZ Investment Advisory Services LLC lifted its stake in shares of Amgen by 1,214.3% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock worth $29,000 after acquiring an additional 85 shares during the last quarter. Evelyn Partners Investment Management LLP purchased a new position in Amgen during the 2nd quarter valued at $32,000. Finally, Activest Wealth Management grew its position in Amgen by 3,433.3% in the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 103 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of AMGN stock opened at $344.65 on Monday. The firm has a market cap of $185.59 billion, a price-to-earnings ratio of 28.18, a PEG ratio of 2.61 and a beta of 0.45. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $345.84. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The company’s 50 day moving average is $307.51 and its 200 day moving average is $295.14.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same quarter last year, the firm earned $5.58 EPS. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 dividend on an annualized basis and a yield of 2.8%. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 10,908 shares of company stock worth $3,674,966 over the last quarter. Insiders own 0.76% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Scotiabank assumed coverage on Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price for the company. Cantor Fitzgerald lifted their price objective on shares of Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Guggenheim upped their target price on shares of Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Finally, Piper Sandler boosted their price target on Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $333.74.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.